Standard BioTools Inc.

NASDAQ:LAB

Medical - Devices

Healthcare
$0.57 +3.38%

+$0.03 today

Market cap
$225.03M
Beta
1.38
P/E (TTM)
-3.5
EPS (TTM)
-$0.24
52W Low $0.79High $1.72

Volume 0.70M

Average 2.91M

LAB Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Standard BioTools Inc.NASDAQ: LAB

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 53.5%

Gross margin was 53.5% in Q1 FY2026, down 1.2 pp from a year earlier. On a trailing-twelve-month basis it was 48.3%, down 1.2 pp year over year. Over 3 fiscal years it widened by 12.0 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
53.5%+10.4 pp QoQ
Last fiscal yearDec 2025
49.9%+1.5 pp YoY
LTMMar 2026
48.3%-1.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.2 pp——
1 year+1.5 pp——
3 years+12.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
49.9%
Year-over-year change
+1.5pp

Gross Margin vs competitors

How LAB compares with its peers on the latest reported figures

  • LAB's LTM Mar 2026 gross margin of 48.3% is the 8th highest of the 10 companies compared; the peer median is 67.8%.
  • Its year-over-year change of -1.2 pp is the 6th highest of 10, against a peer median of -0.5 pp.
  • Over three fiscal years its change of +12.0 pp compares with a peer median of -1.1 pp.
LAB Competitors Peer median
Gross Margin for LAB and competitors
Company Period LTM level YoY 3-year change
ADCTADC Therapeutics S.A.LTM Mar 202690.7% -2.0 pp-7.9 pp
CBLLCeriBell, Inc.LTM Mar 202687.7% +0.5 pp+5.0 pp
TMCITreace Medical Concepts, Inc.LTM Mar 202679.7% -0.5 pp-0.8 pp
KIDSOrthoPediatrics Corp.LTM Mar 202673.1% +0.3 pp-1.1 pp
BVSBioventus Inc.LTM Mar 202667.8% +0.6 pp+2.7 pp
CTKBCytek Biosciences, Inc.LTM Mar 202651.7% -3.2 pp-9.7 pp
AVNSAvanos Medical, Inc.LTM Mar 202648.6% -6.2 pp-7.9 pp
LABStandard BioTools Inc.LTM Mar 202648.3% -1.2 pp+12.0 pp
SYSo-Young International Inc.LTM Mar 202646.0% -12.3 pp-21.0 pp
VREXVarex Imaging CorporationLTM Apr 202633.6% -0.2 pp+1.4 pp
CGEMCullinan Therapeutics, Inc.FY2025— ——
Peer median (excluding LAB) 67.8%-0.5 pp-1.1 pp

Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue130.58M97.95M106.34M174.43M85.33M
Cost of Revenue61.21M60.9M55.89M90.17M42.79M
Gross Profit69.37M37.05M50.45M84.26M42.54M
Gross Margin53.1%37.8%47.4%48.3%49.9%
Research & Development37.94M37.38M25.95M62.41M25.99M
Selling, General & Admin98.89M102.29M87.54M156.61M109.86M
Operating Expenses136.83M153.26M127.05M259.5M135.85M
Depreciation & Amortization15.57M15.03M15.18M16.86M6.98M
EBITDA(44.27M)(173.57M)(54.46M)(118.14M)(89.69M)
EBITDA Margin-33.9%-177.2%-51.2%-67.7%-105.1%
Operating Income(67.46M)(116.21M)(76.6M)(175.24M)(93.31M)
Operating Margin-51.7%-118.6%-72.0%-100.5%-109.3%
Interest Income02.23M5.57M20.2M9.18M
Interest Expense3.82M4.33M4.57M3.32M26K
Other Income / Expenses3.8M(76.72M)2.4M36.92M(3.4M)
Income Before Tax(63.66M)(192.93M)(74.2M)(138.31M)(96.7M)
Pre-Tax Margin-48.8%-197.0%-69.8%-79.3%-113.3%
Income Tax Expense(4.42M)(2.83M)452K573K(37.88M)
Net Income(59.24M)(190.1M)(74.66M)(138.89M)(74.9M)
Net Margin-45.4%-194.1%-70.2%-79.6%-87.8%
EPS (Basic)(0.78)(2.43)(0.94)(0.52)(0.20)
EPS (Diluted)(0.78)(2.43)(0.94)(0.52)(0.20)
Weighted Avg Shares75.79M78.31M79.16M352.67M381.62M
Weighted Avg Shares (Diluted)75.79M78.31M79.16M352.67M381.62M

Standard BioTools Inc.

NASDAQ:LAB

Intrinsic Alpha fair value

Locked

Current Price

$0.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.